Welcome to our dedicated page for PepGen news (Ticker: PEPG), a resource for investors and traders seeking the latest updates and insights on PepGen stock.
PepGen Inc. (Nasdaq: PEPG) is a clinical-stage biotechnology company developing next-generation oligonucleotide therapies for severe neuromuscular and neurological diseases. News about PEPG often centers on progress with its Enhanced Delivery Oligonucleotide (EDO) platform and its lead investigational candidate, PGN-EDODM1, in myotonic dystrophy type 1 (DM1).
Investors following PepGen’s news can expect updates on clinical trial milestones from the FREEDOM-DM1 Phase 1 single ascending dose study and the FREEDOM2-DM1 Phase 2 multiple ascending dose trial, including reported splicing correction data, safety observations, and study enrollment status. The company has highlighted results such as mean splicing correction in DM1 patients and described PGN-EDODM1 as generally well tolerated at evaluated doses in its communications.
PepGen’s news flow also includes corporate and financing announcements, such as underwritten public offerings of common stock under a shelf registration statement on Form S-3, with stated use of proceeds to fund the FREEDOM-DM1 and FREEDOM2-DM1 trials and general corporate purposes. Regulatory and intellectual property developments, including the issuance of a U.S. composition of matter patent for PGN-EDODM1 and FDA Orphan Drug and Fast Track designations for DM1, are additional themes in the company’s press releases.
Other PEPG news items feature executive and governance updates, such as the appointment of a Chief Business and Legal Officer and option repricing actions under the company’s equity plans, as well as participation in investor and scientific conferences where PepGen’s data are presented. For readers tracking PEPG stock, this news page provides a centralized view of clinical, regulatory, financial, and corporate developments that shape the company’s clinical-stage pipeline and capital strategy.
PepGen (NASDAQ: PEPG), a clinical-stage biotechnology company, has announced the pricing of a public offering of 31,250,000 shares of common stock at $3.20 per share, aiming to raise $100 million in gross proceeds.
The offering, expected to close around September 26, 2025, includes a 30-day option for underwriters to purchase up to 4,687,500 additional shares. Leerink Partners and Stifel are serving as joint bookrunning managers. The proceeds will fund ongoing research and clinical development, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, along with working capital and general corporate purposes.
PepGen (NASDAQ:PEPG), a clinical-stage biotechnology company focused on oligonucleotide therapies for neuromuscular and neurological diseases, has announced a proposed public offering of common stock and pre-funded warrants.
The offering includes shares of common stock and pre-funded warrants for certain investors, with a 30-day option for underwriters to purchase additional shares. Leerink Partners and Stifel are serving as joint book-running managers. The proceeds will fund ongoing research and clinical development, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as working capital and general corporate purposes.
PepGen (Nasdaq: PEPG) announced groundbreaking clinical data from its FREEDOM-DM1 Phase 1 study for myotonic dystrophy type 1 (DM1) treatment. The company's drug candidate PGN-EDODM1 achieved a remarkable 53.7% mean splicing correction at 15 mg/kg dosing - the highest ever reported in DM1 patients.
The trial demonstrated 100% patient response rate with improved splicing correction. Safety data showed the treatment was generally well-tolerated, with only mild or moderate adverse events. The company previously reported 12.3% and 29.1% splicing correction at 5 mg/kg and 10 mg/kg doses respectively, showing greater than dose-proportional increases.
PepGen plans to report results from its multiple ascending dose (MAD) study's first cohort in Q1 2026.
PepGen (Nasdaq: PEPG) has reported Q2 2025 financial results and corporate updates, highlighting progress in their myotonic dystrophy type 1 (DM1) program. The company has completed patient dosing in the 15 mg/kg cohort of the FREEDOM trial for PGN-EDODM1, with topline data expected in early Q4 2025.
Based on positive splicing correction results and safety data, PepGen will conclude the FREEDOM trial at the 15 mg/kg dose level and transition to FREEDOM2, their Phase 2 multiple ascending dose study. The company expects to report results from the 5 mg/kg cohort of FREEDOM2 in Q1 2026.
Financial highlights include $74.7 million in cash and equivalents as of June 30, 2025, with runway into Q2 2026. Q2 2025 net loss was $23.1 million, or $(0.70) per share, compared to $28.3 million in Q2 2024.
PepGen (Nasdaq: PEPG) has appointed Kasra Kasraian, PhD as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations. He joins from bluebird bio, where he most recently served as Senior Vice President of Quality, Regulatory Affairs, and CMC Sciences, playing a key role in the approval and launch of three gene therapy products: SKYSONA™, ZYNTEGLO™, and LYFGENIA™.
Previously, Dr. Kasraian held leadership positions at Zafgen, Biogen, Wyeth Biotech, Pfizer, and Genetics Institute. At Biogen, his CMC team led the submission and approval of 3 BLAs/MAAs. He holds a PhD in Pharmaceutical Sciences and BS in Chemical Engineering from the University of Kentucky.
PepGen (Nasdaq: PEPG), a clinical-stage biotechnology company focused on developing next-generation oligonucleotide therapies for severe neuromuscular and neurological diseases, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's President and CEO, James McArthur, PhD, will deliver a corporate presentation on Wednesday, April 9, 2025, at 1:30pm ET. Investors and interested parties can access the webcast through PepGen's website investor section, and a replay will remain available for 90 days after the presentation.
PepGen (Nasdaq: PEPG), a clinical-stage biotechnology company focused on oligonucleotide therapies for neuromuscular diseases, has announced two strategic appointments to its Board of Directors. Lisa Wyman, current Chief Technical and Quality Officer at Scholar Rock, and Dr. Mitchell H. Finer, co-founder and Strategic Advisor for ElevateBio, join the board.
Wyman brings expertise in scaling manufacturing for clinical trials and regulatory navigation, having previously led technical operations at Generate:Biomedicines and Acceleron Pharma, where she contributed to the company's $11.5B acquisition by Merck. Dr. Finer brings 34+ years of genetic therapy experience, having led development of four approved therapies at bluebird bio and holding executive positions across multiple biotech companies.
These appointments aim to strengthen PepGen's board expertise as the company advances its mid-stage clinical trials and Enhanced Delivery Oligonucleotide platform development.
PepGen (Nasdaq: PEPG) announced its upcoming participation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, featuring two oral presentations and five posters. The presentations will showcase data from two significant clinical trials:
1. The CONNECT1-EDO51 Phase 2 study evaluating PGN-EDO51 for Duchenne muscular dystrophy (DMD)
2. The FREEDOM-DM1 Phase 1 study of PGN-EDODM1 for myotonic dystrophy type 1 (DM1)
The conference, scheduled for March 16-19, 2025, will include poster presentations on the Enhanced Delivery Oligonucleotide (EDO) Platform, nonclinical data for both drug candidates, and detailed information about both clinical trials. All presentations will be made available on PepGen's website after the conference.